Valuation: Mineralys Therapeutics, Inc.

Market Cap 1.37B 1.23B 1.13B 1.02B 1.92B 130B 1.96B 13.45B 5.42B 68.69B 5.16B 5.05B 217B P/E 2026 *
-3.47x
P/E 2027 * -6.25x
Enterprise Value 1.12B 999M 917M 834M 1.56B 106B 1.59B 10.95B 4.41B 55.91B 4.2B 4.11B 177B EV / Sales 2026 *
-
EV / Sales 2027 * 14.4x
Free-Float
97.47%
Yield 2026 *
-
Yield 2027 * -
1 day-14.47%
1 week-24.37%
Current month-14.47%
1 month-34.19%
3 months-39.07%
6 months-46.86%
Current year-57.15%
1 week 15.42
Extreme 15.42
22.48
1 month 15.42
Extreme 15.42
24
Current year 15.42
Extreme 15.42
37.7
1 year 15.42
Extreme 15.42
47.65
3 years 5.85
Extreme 5.85
47.65
5 years 5.85
Extreme 5.85
47.65
10 years 5.85
Extreme 5.85
47.65
Manager TitleAgeSince
Chief Executive Officer 62 2020-10-31
Director of Finance/CFO 48 2022-02-28
Chief Tech/Sci/R&D Officer 72 2026-08-09
Director TitleAgeSince
Director/Board Member 62 -
Chairman 49 2019-05-30
Director/Board Member 58 2021-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Sell

Chief Executive Officer

-75,000 0.0986%
9/22/26
Catalys Pacific LLC
SellCompany -104,320 0.1371%
9/21/26 Exercice

Chief Commercial Officer

22,314 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
-14.47%-24.37%-61.94%+99.36% 1.61B
-2.37%-5.03%+39.49%+62.39% 63.77B
-2.87%+0.49%+11.11%+69.18% 56.37B
+0.62%+2.11%+16.96%+102.56% 54.62B
-3.33%-5.54%+19.39%+35.69% 44.06B
-2.45%-2.59%+16.36%+98.45% 42.11B
-1.64%+2.32%+219.80%+789.69% 41B
-5.47%+24.76%+101.20%+87.34% 34.92B
+0.21%+1.05%+14.81%+46.96% 32.82B
-2.90%+17.12%-42.35%+337.07% 24.7B
Average -3.47%+3.72%+33.48%+172.87% 39.6B
Weighted average by Cap. -2.21%+4.71%+44.20%+163.29%

Financials

2026 *2027 *
Net sales - 84.31M 75.27M 69.07M 62.83M 118M 7.98B 120M 825M 333M 4.21B 316M 310M 13.31B
Net income -383M -342M -313M -285M -534M -36.21B -545M -3.74B -1.51B -19.11B -1.44B -1.4B -60.37B -223M -199M -182M -166M -311M -21.07B -317M -2.18B -878M -11.12B -835M -818M -35.13B
Net Debt -256M -228M -210M -191M -357M -24.22B -365M -2.5B -1.01B -12.78B -960M -940M -40.38B -160M -143M -131M -119M -224M -15.16B -228M -1.57B -631M -8B -601M -588M -25.27B
Projected Income Statement - Annual - Mineralys Therapeutics, Inc.
Logo Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.
Employees
76
Date Price Change Volume
26-11-02 US$15.55 -14.47% 4,589,150
26-10-30 US$18.18 -14.41% 3,979,591
26-10-29 US$21.24 -0.65% 2,077,152
26-10-28 US$21.38 +1.18% 1,543,455
26-10-27 US$21.13 +2.77% 3,199,926
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Mineralys Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.55USD
Average target price
45.22USD
Spread / Average Target
+190.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mineralys Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MLYS Stock